News for Eton Pharmaceuticals, Inc. (ETON)

U.S. stock futures were lower this morning, with the Dow futures falling around 1% on Monday. Shares of Rocket Companies, Inc. RKT fell sharply in today's pre-...

On March 5, 2025, Opaleye Management Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 260,000 shares of Codexis Inc. (CDXS). This trans

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Eton Pharmaceuticals secures new patent for desmopressin oral solution, driving development for diabetes insipidus treatment.

**media[534909]**

- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval

Eton Pharmaceuticals (ETON) said the FDA has extended the target action date for its market application for ET-400 to May 28 from Feb. 28. Read more here.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart Month was officially declared by President Lyndon B.

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alkermes (ALKS) experienced a significant stock price increase of 5.00%, reaching $31.72 per share with a trading volume of 928,667 shares and a turnover rate o

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

SWK Holdings updates on recent financial activities

Eton Pharmaceuticals (ETON) has acquired the drug Galzin, also known as zinc acetate, for the treatment of Wilson disease, an ultra-rare metabolic condition. Read more here.

**media[504842]**

Adds an additional commercial and strategic rare disease product to Eton's portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic conditi

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE ® Clinical Trial

Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU GOLIKE